MONDAY, June 6, 2022 (HealthDay News) — An exploratory analysis of data from the SURPASS-4 trial has shown that adults with type 2 diabetes and increased cardiovascular risk receiving tirzepatide experience fewer renal complications, especially new onset of macroalbuminuria; these findings were presented at the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
Previous COVID-19 Tied to Increased Risk for Kidney Disease 
Predictors of Prediabetes/T2DM Identified Among U.S. Adolescents 
Differences in Cardiovascular Risk Factor Prevalence ID"d for South Asian Adults 
Sex Hormones Linked to Cardiovascular Events in Men With Type 2 Diabetes 
Bariatric Surgery Tied to Improvement in Performing Household Tasks 
Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity 
Satisfaction With Semaglutide Driven by Effective Weight Loss 
Intermittent Fasting Seems to Have Little to No Effect for Adults With Overweight, Obesity 
